Immuneering Corporation announced the granting of a U.S. composition of matter patent for its cancer drug, atebimetinib, in July. This patent is expected to provide exclusivity until 2042, with potential for patent term extension. Atebimetinib, a deep cyclic inhibitor administered as a once-daily pill, aims to offer longer-lasting benefits by overcoming resistance mechanisms in cancer treatment. Additional patent applications for atebimetinib are currently pending, with expiration anticipated into 2044.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。